Oldfield Partners’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q3
Sell
-51,277
Closed -$2.11M 23
2019
Q2
$2.11M Hold
51,277
0.2% 18
2019
Q1
$2.07M Hold
51,277
0.21% 18
2018
Q4
$2.12M Sell
51,277
-63,662
-55% -$2.64M 0.12% 18
2018
Q3
$4.81M Sell
114,939
-843
-0.7% -$32.5K 0.49% 14
2018
Q2
$3.02M Hold
115,782
0.32% 15
2018
Q1
$3.9M Hold
115,782
0.34% 15
2017
Q4
$3.98M Buy
115,782
+28,774
+33% +$981K 0.3% 15
2017
Q3
$2.95M Hold
87,008
0.24% 16
2017
Q2
$2.13M Buy
87,008
+36,996
+74% +$1.17M 0.19% 16
2017
Q1
$1.41M Hold
50,012
0.13% 17
2016
Q4
$1.54M Hold
50,012
0.12% 14
2016
Q3
$1.61M Hold
50,012
0.12% 14
2016
Q2
$1.67M Hold
50,012
0.13% 14
2016
Q1
$1.41M Hold
50,012
0.12% 17
2015
Q4
$1.04M Hold
50,012
0.09% 16
2015
Q3
$1.49M Hold
50,012
0.11% 15
2015
Q2
$1.59M Hold
50,012
0.09% 16
2015
Q1
$1.65M Sell
50,012
-13,492
-21% -$429K 0.1% 14
2014
Q4
$1.88M Sell
63,504
-8,432
-12% -$242K 0.11% 15
2014
Q3
$2.02M Hold
71,936
0.12% 15
2014
Q2
$2.03M Hold
71,936
0.09% 16
2014
Q1
$2.19M Hold
71,936
0.1% 16
2013
Q4
$1.26M Sell
71,936
-20,236
-22% -$589K 0.07% 16
2013
Q3
$2.51M Hold
92,172
0.13% 15
2013
Q2
$2.45M Buy
+92,172
New +$2.55M 0.16% 18

Other funds holding PFE

Oldfield Partners's PFE Position: Q3 2019 in Review

Oldfield Partners sold out of Pfizer (PFE) in Q3 2019, closing a stake of 51,277 shares — an estimated $2.11M sold.

Oldfield Partners first reported a position in PFE in Q2 2013 and held it in 25 quarters. The position peaked at $4.81M in Q3 2018. 2,323 funds tracked by Wall St. Rank hold PFE as of Q3 2019.

  • Oldfield Partners reported no remaining Pfizer position as of Q3 2019 after selling out during the quarter.
  • Oldfield Partners sold 51,277 Pfizer shares in Q3 2019, an estimated $2.11M.
  • Oldfield Partners first reported a position in Pfizer in Q2 2013 and held it in 25 quarters.
  • Oldfield Partners's Pfizer position peaked at $4.81M in Q3 2018.
  • 2,323 funds tracked by Wall St. Rank held Pfizer as of Q3 2019.

Based on Oldfield Partners's 13F filing for Q3 2019, filed 22 Oct 2019.